Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib Combination in Hormone-Refractory Prostate Cancer
NCT00427999Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2007
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in prostate cancer (PCa), sponsored by Novartis. Primary endpoint: PSA Response Rate at 24 weeks. Started Feb 2007; status: completed.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00427999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00427999.